Cancer clinical trials in the region Nouvelle-Aquitaine

447 currently recruiting clinical trials
Region Nouvelle-Aquitaine
Phase 3 Stomach and esophageal cancer #NCT06346392
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT06393374
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Immunotherapy Chemotherapy
Required previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
17 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Colon cancer Rectal cancer # NCT06642844
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Centre Hospitalier Universitaire de Tours
Phase 3 Lymphoma #NCT06522737
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
SecuraBio
Phase 2 / Phase 3 Multiple myeloma #NCT07095452 #2025-520897-21-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
15 recruiting sites
Abbvie
Phase 2 / Phase 3 Endometrial cancer #NCT03651206 #2024-516782-36-00
Required histologic sub types
Carcinosarcoma
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Targeted therapy
16 recruiting sites
ARCAGY/ GINECO GROUP
Phase 2 / Phase 3 Acute leukemia #NCT07581002 #2025-523724-47-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Chemotherapy Targeted therapy Car-T
6 recruiting sites
Abbvie
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07129993 #2024-516906-47-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Daiichi Sankyo
Phase 2 / Phase 3 Skin cancer #NCT06697301 #2024-512659-19-00
Required histologic types
Melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Radiotherapy
9 recruiting sites
Eikon Therapeutics
Phase 2 / Phase 3 Pancreas cancer #NCT06989437 #2025-522093-36-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
5 recruiting sites
Pfizer